

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

VOLUNTARY ANNOUNCEMENT LATEST BUSINESS UPDATE OF THE GROUP

The board of directors (the “**Board**”) of HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce the latest business update of the Group as follows.

Recently, following the publication of the results of the Phase III clinical study (SYMPHONY-2) of HTD1801, a core product of the Company, in combination with metformin for the treatment of type 2 diabetes in *NEJM Evidence*^[1], a clinical evidence sub-journal of the internationally renowned medical journal *The New England Journal of Medicine* (NEJM), *NEJM Evidence* further published an editorial titled *Berberine-Ursodeoxycholate — Bringing Traditional Chinese Medicine to Our World*^[2]. The editorial highly commended the rigorous design of the randomized controlled clinical study and the continuously accumulating clinical evidence for HTD1801, and pointed out that the research on HTD1801 provided a paradigm for bringing innovative drugs derived from traditional Chinese practice to the world through high-quality clinical studies. The publication of the above study results and the editorial further demonstrates that the clinical achievements of HTD1801 have garnered widespread attention and recognition from the international academic community.

Currently, the Company is actively advancing the commercialization efforts for HTD1801, and is in discussions with certain potential partners regarding potential out-licensing and commercialization collaboration for the first approved indication of HTD1801 in China. Under the potential collaboration, a potential upfront payment, potential development milestone payments, potential sales milestone payments, and potential royalties may be payable to the Company. The Company will issue further announcement(s) in due course based on the progress.

As at the date of this announcement, discussions on the potential transaction are still ongoing, and no legally binding formal agreement has been reached. Uncertainties remain as to whether the potential collaboration will ultimately materialize.

About HTD1801

HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular-kidney-metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome. These two complementary pathways mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that HTD1801 will ultimately be successfully marketed.

Sources:

- [1] Linong Ji, Zhifeng Cheng, et al., HTD1801 in Combination with Metformin for Type 2 Diabetes, NEJM Evidence, 5, 7, (2026). DOI: 10.1056/EVIDoa2500317.
- [2] Binh Ngo, Marc Rendell, Berberine-Ursodeoxycholate — Bringing Traditional Chinese Medicine to Our World, NEJM Evidence, 5, 7, (2026). DOI: 10.1056/EVIDe2600088.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, July 10, 2026

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Dr. LI Jin, Mr. HUNG Tak Wai and Mr. CHEN Mingyu as independent non-executive Directors.